Loading stock data…
GMAB
$26.18-0.26 (-0.98%)
After Hours$25.68-0.50 (-1.91%)· Last close May 11
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Genmab A/S in the Healthcare sector is trading at $26.18. The stock is currently 26% below its 52-week high of $35.43, remaining 9.5% below its 200-day moving average. Technical signals show neutral RSI of 43 and bearish MACD signal, explaining why GMAB maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 43) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$26.18
Potential Upside
26.5%
Whystock Fair Value$33.11
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$37.64+43.8%
Range$32.00 – $48.00
Fundamentals
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diff...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$16.60B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
17.56
Beta
Defensive asset. Lower volatility than the S&P 500.
0.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
21.04%
Volume
Today's trading volume
2.65M
Recent News
Is It Time To Reassess Genmab (CPSE:GMAB) After Mixed Multi‑Year Share Performance
Wondering whether Genmab stock still offers value at current levels, or if the best of the opportunity is already behind it, starts with understanding what the recent price moves really say about expectations. Over the last week the stock is up 4.1%, while the 1 year return sits at 36.3%. This is even though the year to date return is a 12.4% decline and the 3 and 5 year returns are 38.7% and 21.2% declines respectively. These mixed returns have kept attention on Genmab, with recent coverage...
Genmab A/S Q1 Earnings Call Highlights
Genmab A/S (NASDAQ:GMAB) reported first-quarter 2026 results highlighting revenue growth, expanding proprietary product sales, and continued investment in its late-stage pipeline, while maintaining profitability. President and CEO Jan van de Winkel said the company “continued to deliver strong finan
DARZALEX royalties drive Genmab’s Q1 revenue higher amid expansion push
Investing.com -- Genmab reported a 25% year-on-year increase in first-quarter revenue for 2026, driven by strong royalty income from blockbuster cancer drug DARZALEX and multiple sclerosis treatment Kesimpta, as the Danish biotech company continued investing heavily in its late-stage oncology pipeline.
Genmab (GMAB) Rated Outperform on Oncology Pipeline
Genmab A/S (NASDAQ:GMAB) ranks among the most profitable biotech stocks to buy now. Wolfe Research began coverage of Genmab A/S (NASDAQ:GMAB) on March 26 with a price objective of $32 and an Outperform rating. In anticipation of clinical triggers anticipated in 2026, the firm sees the current price dip following a loss in a confirmatory […]
Genmab A/S (GMAB) Rating Lifted by Goldman Sachs on Strong 2026 Catalyst Outlook
We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. Genmab A/S is among the best biotech stocks. TheFly reported on April 22 that The Goldman Sachs Group raised its rating on GMAB from Neutral to Buy and set a price target of $30.50. The upgrade reflected expectations of […]